YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
By Karen Roman Slate Medicines Inc. said it dosed the first participant in Phase 1 of its clinical study evaluating SLTE-1009, the company's subcutaneous antibody candidate for migraine treatment. Phase 1 single-and multiple-ascending dose…
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) signed an all-stock merger agreement with Slate Medicines that would turn the public company into a migraine-focused biotechnology business. Slate is contributing its drug assets, while new investor…
By Karen Roman Fulcrum Therapeutics, Inc. (Nasdaq: FULC) said it is merging with Slate Medicines, Inc. to advance next-generation therapeutics to treat migraine and other headache disorders, with the combining company operating as Slate Me…
Key Points Interested in Fulcrum Therapeutics, Inc.? Here are five stocks we like better. Fulcrum Therapeutics will merge with migraine biotech Slate Medicines in an all-stock transaction expected to close in the fourth quarter of 2026, pe…
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Headache drug specialist Slate Medicines said Monday it will combine with struggling biotechn…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. The updated analyst framework for Fulcrum Therapeutics lifts the Fair Value estimate from US$5.43 to US$5.83 per share.…
As the saying goes, there are many possible reasons for an insider to sell a stock, but only one reason to buy -- they expect to make money. So let's look at two noteworthy recent insider buys. At Fulcrum Therapeutics, a filing with the SE…
Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. For Fulcrum Therapeutics, the modeled fair value has been reset from about US$19.00 to roughly US$5.43, a cut of around…
NEW YORK, June 05, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (NASDAQ: FULC) shares fell approximately 50% on June 1, 2026, after the company disclosed that the FDA had raised class-wide safety concerns about PRC2-targeting agents…
Fulcrum Therapeutics FULC saw its stock crash 51.1% on Tuesday after announcing the discontinuation of its lead candidate, pociredir, for sickle cell disease (SCD). The decision effectively pushes the company back to the pre-clinical stage…
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in California Water Service Group (Symbol: CWT), where a total volume of 8,452 contracts has been traded thus far today, a c…
SAN DIEGO, June 02, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Fulcrum Therapeutics, Inc. (NASDAQ: FULC) or certain of its executive officers violated federal securities laws. The investigation focuses on invest…
The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top 5 Upgrades: Arete upgraded Meta Platforms(META) to Buy…
(RTTNews) - Biotech stocks are showing strong pre-market moves this Tuesday, hinting at possible breakout setups. Assessing sentiment and momentum in the premarket sets the tone for a trader's day. In the Green - Premarket Gainers On Tuesd…
Fulcrum Therapeutics discontinues its pociredir program after the Food and Drug Administration raises concerns. Continue Reading
(RTTNews) - Fulcrum Therapeutics, Inc. (FULC), a clinical-stage biopharmaceutical company, announced the discontinuation of its lead Pociredir program for the treatment of sickle cell disease (SCD) following FDA's feedback regarding the im…
― Decision follows FDA feedback regarding the implications of the secondary malignancies observed with Tazverik®(tazemetostat) and the product’s subsequent global withdrawal on the benefit-risk profile of pociredir in sickle cell disease (…
CAMBRIDGE, Mass., May 08, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare…
Image source: The Motley Fool. DATE Monday, April 27, 2026 at 8:00 a.m. ET CALL PARTICIPANTS Chief Executive Officer — Alexander SapirChief Financial Officer — Alan MussoChief Medical Officer — Iain Fraser Need a quote from a Motley Fool a…
medical research 16 ©Rawpixel Fulcrum Therapeutics Inc. (NASDAQ:FULC) moved higher in pre-market trading on Monday after reporting first-quarter results that topped analyst expectations. The clinical-stage biopharmaceutical firm posted a l…
CAMBRIDGE, Mass., April 27, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Fulcrum) (NASDAQ: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules that improve the lives of patients with rare hemato…
The following companies are expected to report earnings prior to market open on 04/27/2026. Visit our Earnings Calendar for a full list of expected earnings releases. Verizon Communications Inc. (VZ)is reporting for the quarter ending Marc…
Agios Pharmaceuticals stock jumped Tuesday after the company said it would seek an accelerated approval for its sickle cell treatment. Continue Reading
CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading nonprofit providing medical IDs and emergency medical information services, Sickle Cell Disease Association of America, Inc., (SCDAA), the national voi…
CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rar…
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetic…
Stifel analyst James Condulis tells investors that the move lower in Fulcrum Therapeutics (FULC) this morning “surprises us” and looks “overdone.” While the firm believes some thought total mean HbF may comfortably be greater than 20% give…
CAMBRIDGE, Mass., Feb. 06, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare…
CAMBRIDGE, Mass., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare…
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) is one of the 12 best multibagger stocks to buy heading into 2026.Bullish Analyst Sentiment on Fulcrum Therapeutics (FULC) Following Positive Updates from Phase 1b PIONEER Study Following encouragin…
* Fulcrum Therapeutics (FULC [https://seekingalpha.com/symbol/FULC]) on Wednesday announced the pricing of its underwritten public offering of 11.85M shares of its common stock at a public offering price of $13.50 per share, and, in lieu o…
CAMBRIDGE, Mass., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (“Fulcrum”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically…
Fulcrum Therapeutics (FULC [https://seekingalpha.com/symbol/FULC]) on Saturday reported [https://seekingalpha.com/pr/20331012-fulcrum-therapeutics-announces-positive-initial-results-from-the-20-mg-dose-cohort-of-the]positive initial result…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at the Week 6 timepoint (n=12): mean absolute HbF in the 20 mg cohort increased by 9.9% at Week 6 (vs. 5.6% at Week 6 in the 12 mg coh…
CAMBRIDGE, Mass., Dec. 05, 2025 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare…
(RTTNews) - Fulcrum Therapeutics, Inc. (FULC) will present new clinical data from its PIONEER trial in an investor event on December 7, 2025, at 7:00 a.m. ET. PIONEER is a Phase 1b trial of Pociredir, an oral therapeutic, in patients with…